Key Developments For Prana Biotechnology Ltd
Prana Biotechnology Ltd (PRAN.O) (Consolidated Issue listed on NASDAQ Capital Market)
Prana Biotechnology Announces Ownership Interest Of Morgan Stanley Australia Securities Limited
Prana Biotechnology announced that Morgan Stanley Australia Securities Limited is interested in 12,076,175 shares representing 5.18% of the issued share capital of the Company.
Prana Biotechnology Secures AUD6 Million Additional Financing
Prana Biotechnology announced that it has reached agreement to raise AUD6 million to support its R&D programs, to promote its drug development pipeline and to maintain corporate activities. Under the terms of the funding, Prana will issue 30 million ordinary shares ranking equally with the existing ASX listed ordinary shares (equivalent to 3 million ADR’s on NASDAQ) at a price of AUD0.2 per share. The investor will also receive, subject to shareholder approval, 10 million free attaching options each to acquire one ordinary share at an exercise price of 30 cents and expiring four years from the date of issue of the abovementioned shares. The Company will receive AUD5.7 million net of all fees.
Prana Biotechnology Limited Announces Issue Of Shares
Prana Biotechnology Limited announced the issue of 54,500 ordinary shares. The shares will rank Pari Passu with existing ordinary shares.
Prana Biotechnology Allowed Key Patent For PBT2 In United States
Prana Biotechnology announced that it has received a Notice of Allowance from the United States Patent and Trade Mark Office (USPTO), protecting its clinical asset, PBT2, in the USA. The patent entitled, '8-Hydroxyquinoline derivatives' covers the composition of matter of selected families of 8-Hydroxyquinoline compounds, including PBT2 and pharmaceutical compositions containing these compounds.
Prana Biotechnology Secures Patent By European Patent Office
Prana Biotechnology announced that it has secured a patent protecting its clinical drug asset PBT2, with the European Patent office issuing a notice of Decision to Grant in Europe. The patent entitled 8-Hydroxyquinoline derivatives covers the composition of matter of selected families of 8-Hydroxyquinoline compounds, including PBT2 and the uses of such compounds for the treatment of neurological diseases, including Alzheimer’s Disease and Huntington’s Disease. The European patent has a twenty year term expiring on July 16, 2023, with a possible extension of term of up to five years under supplementary protection provisions.
